Grade My Investments
HomeFree Stock Grades › CLPT

ClearPoint Neuro, Inc. (CLPT) Stock Grade

CLPT · Healthcare

C+
Grade updated: July 18, 2026
Computed by the GradeMyInvestments scoring model from revenue growth, profitability, balance-sheet strength, and analyst targets.
Market Cap
$387.4M
P/E Ratio
Revenue Growth (YoY)
+17.8%
Net Margin
-69.1%
Return on Equity
Dividend Yield
None

About ClearPoint Neuro, Inc.'s fundamentals

ClearPoint Neuro is a medical device company with a market capitalization of $387.4 million that has demonstrated solid revenue growth of 17.8% year-over-year, indicating expanding market adoption of its products. However, the company is not yet profitable, operating at a net margin of -69.1% and reporting a net loss in its latest annual statement, which is not uncommon for growth-stage medical device firms investing heavily in development and commercialization. The company does not currently pay a dividend, with cash being retained for operational and strategic purposes.

Track CLPT free — no credit card required. Live grade + monthly AI report →